British women Linda Sinnett , through exposure to asbestos died from peritoneal mesothelioma,who most likely through the transfer of her father's clothes have been exposed to asbestos.

Sinnett's family believes she ingested asbestos fibers are released into the home, especially in the kitchen.where  cleaning  her father's clothes. Sinnett's father was a Great Western Railway works staff, often brings his asbestos work clothes home. The family believes that these fibers by the risk of contamination of food and food preparation area.

When asbestos fibers intake, they can migrate into the peritoneal mesothelial cells, to where. As time goes by, the fibers caused by abnormal cells to develop into cancer, the phenomenon known as peritoneal mesothelioma.

Peritoneal mesothelioma affect the skin lining (also known as the mesothelium) in the chest organs and / or abdomen. Mesothelial cells is a thin layer of liquid, such as heart, lungs, stomach and testicles lubrication and protection agencies.

Like other types of mesothelioma, peritoneal mesothelioma is usually a long incubation period. It usually takes several years or after asbestos exposure to cancer, even decades of diagnosis. Pairs of mesothelioma cases diagnosed each year only 15% - 20% started in peritoneal.

A former sheet metal family still come to terms with the man died earlier this year from Mesothelioma in Portsmouth, UK. Thomson, and no knowledge of his workplace exposure to asbestos, but soon succumbed to the asbestos cancer mesothelioma months after the incident, his diagnosis.

Williamson's widow, Betty, and now say that she and events surrounding the tragic death of her husband, she also makes publicly thank local charities, Hasag, who assisted, and suggested that her family following the diagnosis of mesothelioma, Mr. Williamson .

Mrs. Williamson said her husband had worked in the sheet metal factory 20 years of medical investigation. In the meantime, do not realize that the work around the danger. The company failed to inform them,and doesn't  provide safety devices to protect him or other workers. Asbestos mesothelioma is a rare aggressive cancer that attacks the primary cause of lung and other organs, and life, every year thousands of such cases.

"He couldn't think where he had got it," Williamson said. "He has never actually worked with it (sbestos). He was never ever concerned about it."

For decades, there is no indication, or until it has developed into an incurable stage of symptoms. Often, people do not know that they are exposed to asbestos as Williamson in the same circumstances, and doctor does not realize that it is mesothelioma or other asbestos-related diseases.

Sheet Metal and shipbuilding industry is  the highest risk of exposure to asbestos . According to statistics, men died in Portsmouth, United Kingdom, more than any other parts of mesothelioma in the region, and has the sixth-highest Portsmouth deaths of men in the UK unemployment rate for mesothelioma.

As many as 1,200 people walked and remembered through the night at the American Cancer Society's Relay for Life event Saturday afternoon through Sunday morning in Lampe Park.
“There was a huge turnout,” said Relay for Life chairwoman Katrina Rowe. “There were over 700 registered participants and we had even more at the event. People ended up bringing family and friends and others from the community just showed up.
“We raised $112,000 during relay and there's still money coming in. We're hoping the total will be close to $120,000. With this economy, we were just going to try to do our best, but that's a lot of money.”
Last weekend's event was Gardnerville's 12th annual Relay for Life. At least 63 area teams held fundraisers during the year to contribute to the American Cancer Society's Relay for Life.
The national Relay for Life was created in 1985 to remember friends and loved ones who died from cancer and to raise money to fight the disease.
“Relay for Life is about walking — cancer doesn't sleep and neither will we — and each team tries to keep someone walking throughout the night,” said Rowe. “There were a lot of fun things to do.”
Events included the Carson Valley Active 20-30 Club cooking hamburgers and hot dogs, a bachelor auction that made more than $900, a shock booth by G.E. Energy, hot air balloon, music and a talent show. Relay walkers were greeted Sunday with sunrise yoga and breakfast put on by the Knights of Columbus.
“During relay, we honor survivors with dinner, have the luminaria ceremony when it gets dark,” Rowe said. “It's a remembrance of people who died or who are struggling with the disease.
“This year's theme was ‘Who do you know?' and by the looks of the turnout, there were a lot of people who were affected by cancer.
“It's not just about the people who passed, but it's about the survivors, the caregivers, people who are undergoing treatment for cancer. It even involves someone who had a mole removed and is waiting for the results.”
Relay for Life teams will be hosting fundraising events through August. Team Nailing a Cure will still be flocking with their flamingos. There will be a bachelor auction at Centerfield Sports Bar & Grill in Gardnerville on Aug. 21.
“The more money we make, the more chances we have of finding a cure,” said Rowe.
Rowe acknowledged the Douglas County Parks & Recreation Department for allowing the park to be reserved for Relay for Life.
“Relay is a community event — you feel the hometown aspect of it,” she said.
“Relay is a lot of work at the time, and there's so many people. But it was high energy and a lot of fun. I'm looking forward to next year.”

Heidelberg, July 29th, 2009 - Apogenix GmbH, a biopharmaceutical company developing novel drugs for malignant and inflammatory diseases, today announced that the company has received federal research grants of EUR 2.6 million as one of the companies belonging to the Biotechnology Cluster Rhine-Neckar (BioRN).

In 2008, the BioRN cluster was awarded a total of EUR 40 million as one of the five most important German high-tech regions in the Top Cluster Contest of the German Federal Ministry of Education and Research. The funds will be dedicated to two of Apogenix´ research projects in the field of cancer and inflammatory diseases.

The first program focuses on the development of an IL-4 inhibitor for the treatment of cancer – especially solid tumors which are resistant to chemotherapy and radiation. IL-4 is a cytokine expressed by cancer cells as well as cancer stem cells blocking apoptosis and thereby rendering therapies such as chemotherapy or radiation ineffective. Apogenix´ approach is based on blocking the IL-4 receptor in order to make cancer cells susceptible for treatment. The program will be coordinated by Apogenix and conducted in close collaboration with the research group of Prof Peter Krammer at the German Cancer Research Center (DKFZ).

The second program aims to accelerate the development of inhibitors of the CD95 ligand (CD95L), specifically APG103, for the treatment of chronic inflammatory diseases. CD95 is a receptor inducing apoptosis as well as migration of, e.g. inflammatory cells. Apogenix aims to inhibit CD95 ligand, thereby preventing inflammatory processes right from the start. The research activities to explore the therapeutic potential of APG103 and additional CD95 inhibitors, and to generate preclinical data on these compounds is conducted in collaboration with the research group of Dr Ana Martin-Villalba at the German Cancer Research Center and coordinated by Apogenix. Both programs include activities such as the construction, manufacturing and characterization of novel IL-4 and CD95L inhibitors, as well as pharmacological, pharmacokinetic, safety and mode of action studies. Apogenix´ goal is to advance the most promising IL-4 and CD95L inhibitors to clinical development.

”We are proud about receiving these two research grants,” said Dr Thomas Höger, Chief Executive Officer of Apogenix. “The grants underline the quality and the potential of the research activities of both Apogenix and its collaboration partners at the German Cancer Research Center. With these funds, we hope to accelerate our programs and provide improved treatment options for patients with cancer and chronic inflammatory diseases.”

###

About Apogenix

Apogenix is a biopharmaceutical company developing novel drugs based on the targeted modulation of CD95 and Interleukin-4-receptor mediated signalling pathways. These pathways play an important role in a variety of malignant and inflammatory diseases.

Apogenix is a spin-out from the German Cancer Research Center (DKFZ), and is based in Heidelberg, Germany. Since 2005, the company has raised EUR 43 million in two financing rounds, mainly from the family of the renowned biotech investor and SAP co-founder Dietmar Hopp.

Contact information

Dr Thomas Höger

Apogenix GmbH

Im Neuenheimer Feld 584

D-69120 Heidelberg

Phone: +49 (6221) 5 86 08-0

Fax: +49 (6221) 5 86 08-10

contact@apogenix.com

www.apogenix.com<http://www.apogenix.com>

Ines-Regina Buth

akampion

Platz vor dem Neuen Tor 2

D-10115 Berlin

Phone: + 49 (30) 23 63 27 68

Fax: +49 (30) 23 63 27 69

ines@akampion.com

www.akampion.com<http://www.akampion.com>

Dr. Ludger Weß

Managing Partner

akampion

Saseler Loge 6b D-22393 Hamburg Germany T: +49 (0)40 88 16 59 64 F: +49 (0)40 88 16 59 65 M: +49 (0)160 96 65 29 58 ludger@akampion.com

USt-Id. DE163019175

Results of the 30-month study based in Mexico City are expected to be released later this year

Syracuse, NY 7/07/2009 02:35 下午 GMT (FINDITT)

The National Institute of Cancerologia in Mexico City, Mexico will shortly be releasing results of a 30-month study to determine the efficacy of a combination drug therapy designed to improve the response and survival rates of pleural mesothelioma patients undergoing chemotherapy.

The study, which followed 30 pleural mesothelioma patients from September 2007 to April 2009, was conducted to determine whether a combination of two chemotherapy drugs, liposomal doxorubicin and Cisplatin®, would improve survival rates of these patients.

Most single-drug chemotherapy regimes have resulted in response rates of less than 20 percent. Combination therapies, including therapy with non-liposomal doxorubicin and cisplatin, have produced only slight higher response rates of about 25 percent.

Researchers hope the liposomal form of doxorubicin will be more readily absorbed by cancer patients, improving survival rates and helping patients remain comfortable longer. Liposomes are “bubble-like” structures composed of the same material as cell membranes, and are often sued to deliver drugs in certain conditions where normal delivery might result in toxic side effects, or where deeper penetration of the affected cells is required.

Pleural mesothelioma is the most common form of mesothelioma, affecting the lining of the lungs and developing as a result of asbestos exposure. Pleural mesothelioma develops as the tissue which surrounds the lungs becomes embedded with tiny fibers of inhaled asbestos, and can occur decades after initial exposure. The most prevalent mesothelioma causes include direct or indirect workplace exposures. Currently, there is no cure for mesothelioma, although symptoms can be treated to improve comfort in those affected by the condition.

University of Wisconsin Professor Dr. H. Ian Robins, an oncologist who specializes in the treatment of mesothelioma and other cancers, is one of the many US-based physicians who specialize in the study of asbestos-caused cancers. There is no cure for mesothelioma, but many oncologists like Dr. Robins are devoted to the study of this disease and have the hope that a cure is not far off.

Stars and Stripes
Pacific edition, Thursday, July 9, 2009

A court has ordered the Japanese government to pay about $786,000 to the family of a Japanese employee who died from an asbestos-related disease while working at Yokosuka Naval Base.

Judge Haruhiko Sakae of the Yokohama District Court in Yokosuka ruled Monday that both the Japanese government and U.S. Forces Japan — employer and user, respectively — neglected to take necessary precautions until 1987.

Hitoshi Taima began working at the base in 1977 and was exposed to asbestos while installing and maintaining air-conditioning units, according to Michitaka Hayashi, board member of the Yokosuka-based Pneumoconiosis and Asbestos Victim Relief Fund.

Taima was diagnosed in April 2006 with malignant mesothelioma caused by asbestos. A year later the Navy recognized his disease as a work-related illness, Hayashi said.

Taima filed a lawsuit in March 2007, based on the Special Civil Act under the U.S.-Japan Status of Forces Agreement, demanding the Japanese government pay about $940,000 in compensation. The act states that, as employer, Japan is liable for worker accidents and health issues.

The ruling said that while the government was aware of health hazards caused by asbestos before 1977, it failed to take necessary precautions until 1987.

Taima died in 2007 at age 51.

Hayashi said Taima was the 42nd asbestos victim at U.S. military bases who was awarded compensation by Japanese courts.

Ford Motor Company will not be required to pay the full legal costs of an asbestos victim.

Mesothelioma Cancer News (Australia) – Ford Motor Company has been excused from having to pay the full legal costs of an asbestos victim who previously worked for the company. As reported by The Age, the West Australian Court of Appeal ruled Friday that the automaker would not have to pay the full amount of attorneys fees and court costs for the family of Antonino Lo Presti, who passed away in April from an asbestos related disease.

As noted in the report, Lo Presti was the first motor mechanic in Australia awarded a verdict in an asbestos related negligence case against an auto company. He was awarded $840,000 in damages for being exposed to asbestos while working for the company in the 1970s and 1980s. However, per the court’s ruling, Ford will only be required to pay between 50 and 65 percent of Lo Presti’s legal costs.

52 miners working at Minnesota’s Iron Range have been found to have mesothelioma, an asbestos-related cancer. Mesothelioma has been traditionally associated with asbestos exposure; however, there is no known asbestos in the iron ore deposit. When asbestos fibers become airborne, they are breathed into the lungs where serious illness can develop up to 40 years after exposure.
The Minnesota Department of Health will be conducting studies on the miners to determine if they have been exposed to asbestos at any time in their lives, prior to working at Iron Range. Some of the mine workers believe that the taconite dust in the mines is the cause of their illness. No studies to date have proven that mesothelioma can be caused by airborne particles other than asbestos.
Mine officials want to know whether iron ore mining can be linked to mesothelioma. The company is planning an expansion at its Northshore mine, and they want answers so they can move forward with the plan. The mining representatives support the health study, but they don't believe the taconite dust is dangerous.
A meeting will be held June 25th as the next step in the effort to determine the cause of the high rate of mesothelioma in the Iron Range workers. The meeting will lay out the plans for conducting a major survey of taconite workers' lung health. Participants will get an x-ray, blood test, and breathing test. The study gets underway this summer.

COLUMBUS, Ohio (AP) -- Legislative floor actions in the House of Representatives and Senate from Tuesday, June 9.

HB 211 MESOTHELIOMA MONTH -- To designate September as "Mesothelioma Month."

ANN ARBOR, Mich. — Women are under-represented in clinical cancer research published in high-impact journals, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center.

Taking into account the incidence of particular types of cancer among women, studies included a smaller proportion of women than should be expected. The analysis looked specifically at studies of cancer types that were not gender specific, including colon cancer, oral cancers, lung cancer, brain tumors and lymphomas.

The authors looked at 661 prospective clinical studies with more than 1 million total participants. Results of this study appear online in the journal Cancer and will be published in the July 15 print issue.

“In the vast majority of individual studies we analyzed, fewer women were enrolled than we would expect given the proportion of women diagnosed with the type of cancer being studied. We’re seeing it across the board in all cancer types,” says study author Reshma Jagsi, M.D., D.Phil., assistant professor of radiation oncology at the U-M Medical School.

“It’s so important that women are appropriately represented in research. We know there are biological differences between the sexes, as well as social and cultural differences. Studies need to be able to assess whether there are differences in responses to treatment, for example, between women and men,” she adds.

The National Institutes of Health’s Revitalization Act of 1993 explicitly calls out the importance of including women in clinical research, noting that clinical trials should enroll adequate numbers of women to allow for subgroup analysis.

The U-M researchers found that studies reporting government funding did include higher numbers of women participants, but the impact was modest – 41 percent, compared to 37 percent for studies not receiving government funding.

Traditionally, researchers were told not to include people of vulnerable populations in their studies. This group included women of childbearing age. “By protecting them from research, we’re excluding them,” Jagsi notes.

Previous studies have found some barriers to clinical trial participation are lack of information, fear and a perception of interfering with personal responsibilities, such as child care.